Dr Paul Huang leads our Molecular and Systems Oncology Team, located within the Division of Molecular Pathology.

The team seeks to understand how networks of signalling proteins control tumour progression and drug resistance in cancer, and identifies drugs that could overcome this resistance in patients.

This work brings together information from biochemistry, computational modelling, molecular pathology and proteomics.

Dr Huang is keen to collaborate with industry partners on a number of projects.

In particular, the team has significant experience in identifying biomarkers of patient benefit, and in patient stratification, which they are keen to share with commercial partners.

These partners could include providers of companion diagnostics and pharmaceutical companies who want to develop new biomarkers for their drugs.